Biological Efficacy and Plasma Norethisterone Levels of Orally Administered Norethisterone Enanthate in Rat and Hamster
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Seco-Steroids C07C)
CPC - C07J - 2021.08 C07J STEROIDS (seco-steroids C07C) Definition statement This place covers: Compounds containing a cyclopenta[a]hydrophenanthrene skeleton (see below) or a ring structure derived therefrom: • by contraction or expansion of one ring by one or two atoms; • by contraction or expansion of two rings each by one atom; • by contraction of one ring by one atom and expansion of one ring by one atom; • by substitution of one or two carbon atoms of the cyclopenta[a]hydrophenanthrene skeleton, which are not shared by rings, by hetero atoms, in combination with the above defined contraction or expansion or not, or; • by condensation with carbocyclic or heterocyclic rings in combination with one or more of the foregoing alterations or not. Preparation of steroids including purification, separation, stabilisation or use of additives unless provided for elsewhere, as specified below. Treatment and modification of steroids provided that • the treatment is not provided for elsewhere and • the resultant product is a compound under the subclass definition. Relationships with other classification places In class C07, in the absence of an indication to the contrary, a compound is classified in the last appropriate place, i.e. in the last appropriate subclass. For example cyclopenta [a] hydrophenantrenes are classified in subclass C07J as steroids and not in subclasses C07C or C07D as carbocyclic or heterocyclic compounds. Subclass C07J is a function-oriented entry for the compounds themselves and does not cover the application or use of the compounds under the subclass definition. For classifying such information other entries in the IPC exist, for example: Subclass A01N: Preservation of bodies of humans or animals or plants or parts thereof; biocides, e.g. -
Pp375-430-Annex 1.Qxd
ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay, -
Guidelines for the Management of Heavy Menstrual Bleeding
i GUIDELINES FOR THE MANAGEMENT OF HEAVY MENSTRUAL BLEEDING Prepared by a Working Party on behalf of the National Health Committee ii MAY 1998 Women reporting with heavy menstrual bleeding 50% of women have menstrual blood loss Full menstrual history ● Examination ● Full blood count note1 Yes Prolonged irregular cycles No Refer Yes Abnormal exam specialist uterine size >12wks note 2 No mild or severe anaemic moderate treat < 80 g/l (80-115g/l) anaemia No Assess risk of endometrial hyperplasia low Offer medical therapy ● risk Unexplaine bodyweight 90kg heavy menstrual ● note5 note 6 age 45 years <2% bleeding ● other risk factors have 90% of women note 3 ● levonorgestrel endometrial >8% have hyperplasia intrauterine system ● tranexamic acid ● Assess endometrium nonsteroidal ● transvaginal ultrasound antiinflammatory agents ● (TVS) norethisterone long course or normal ● oc pill endometrium ● ● endometrial biopsy if danazol if one medical therapyfails endometrium 12mm others can be used note 7 or if TVS not available note 4 Treatment Hyperplastic endometrium success? or carcinoma No Yes Refer to specialist for hysteroscopic evaluation Continue Refer specialist me d i c a l for surgery therapy note8 note9 iii note 1 O In women <20 years old pelvic examination is unlikely to contribute to management of heavy bleeding (C) and the likelihood of pathology is small (C) O Increased likelihood (70%) of heavy menstrual blood loss >80mls/cycle if Hb <120g/l (A) O Consider pictorial blood loss assessment charts (appendix 6.5) for women with normal -
Toiminta Unita on Ulla La Mungukurti |
TOIMINTAUNITA USON 20180071390A1ULLA LA MUNGUKURTI | ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0071390 A1 PATEL et al. (43 ) Pub . Date : Mar . 15 , 2018 ( 54 ) COMPOSITIONS OF PHARMACEUTICAL A61K 9 / 06 (2006 .01 ) ACTIVES CONTAINING DIETHYLENE A61K 9 /00 (2006 .01 ) GLYCOL MONOETHYL ETHER OR OTHER A61K 31 /573 ( 2006 .01 ) ALKYL DERIVATIVES A61K 31/ 565 ( 2006 .01 ) A61K 31/ 4439 ( 2006 . 01 ) ( 71 ) Applicant : THEMIS MEDICARE LIMITED , A61K 31 / 167 ( 2006 . 01 ) Mumbai (IN ) A61K 31 / 57 (2006 . 01) (52 ) U . S . CI. (72 ) Inventors : Dinesh Shantilal PATEL , Mumbai CPC .. .. .. A61K 47 / 10 ( 2013 . 01 ) ; A61K 9 /4858 ( IN ) ; Sachin Dinesh PATEL , Mumbai ( 2013 .01 ) ; A61K 9 /08 ( 2013 .01 ) ; A61K 9 / 06 ( IN ) ; Shashikant Prabhudas ( 2013 .01 ) ; A61K 9 / 0014 ( 2013 .01 ) ; A61K KURANI, Mumbai ( IN ) ; Madhavlal 31/ 573 ( 2013 .01 ) ; A61K 31 /57 ( 2013 .01 ) ; Govindlal PATEL , Mumbai ( IN ) A61K 31/ 565 ( 2013 .01 ) ; A61K 31 /4439 (73 ) Assignee : THEMIS MEDICARE LIMITED , ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Mumbai (IN ) 9 /0048 ( 2013 .01 ) ; A61K 9 /0019 (2013 .01 ) ( 57 ) ABSTRACT (21 ) Appl. No .: 15 / 801, 390 The present invention relates to pharmaceutical composi tions of various pharmaceutical actives, especially lyophilic ( 22 ) Filed : Nov . 2 , 2017 and hydrophilic actives containing Diethylene glycol mono ethyl ether or other alkyl derivatives thereof as a primary Related U . S . Application Data vehicle and /or to pharmaceutical compositions utilizing (62 ) Division of application No. 14 /242 , 973 , filed on Apr. Diethylene glycol monoethyl ether or other alkyl derivatives 2 , 2014 , now Pat. No. 9 , 827 ,315 . -
Combined Estrogen–Progestogen Menopausal Therapy
COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem. -
NORETHISTERONE This Document Should Be Read in Conjunction with This DISCLAIMER
King Edward Memorial Hospital Obstetrics & Gynaecology ADULT NORETHISTERONE This document should be read in conjunction with this DISCLAIMER Presentation Tablets: 350microg Tablets: 5mg Combination products: Tablets (Norimin 28®): norethisterone 500microg with ethinylestradiol 35microg As part of HRT: see Estrogen (Oestrogen) HRT Dose Contraception Oral: Progesterone only pill (POP): 350microg daily Combined oral contraceptive pill (COCP): ONE tablet daily Endometriosis Oral: 5-10mg once daily for at least 4-6 months Menstrual disorders (e.g. heavy menstrual bleeding) Oral: Initially: 5mg 3 times daily for 10 days. Higher doses have been used; seek specialist advice. To prevent recurrence (anovulatory): 5mg once or twice daily for 10- 14 days in seconf half of cycle To prevent recurrence (ovulatory): 5mg 3 times daily for days 5-26 of cycle Hormone replacement therapy (HRT) Oral: 1.25mg daily for 10-14 days each month, to be taken with continuous estrogen. Refer to Estrogen (Oestrogen) HRT Adult Medication Monograph Page 1 of 1 Norethisterone – Adult Administration Oral To be taken at the same time each day (or within 3 hours of the usual dose time). For Contraception: Start 4 weeks after the birth of baby (increased risk of abnormal vaginal bleeding if started earlier) Pregnancy 1st Trimester: Contraindicated 2nd Trimester: Contraindicated 3rd Trimester: Contraindicated Breastfeeding Considered safe to use. Progestogens are the preferred hormonal contraceptives as they do not inhibit lactation. Clinical Guidelines Estrogen (Oestrogen) HRT and Policies Progesterone Only Pill Contraception: Post Partum Gynaecology (Non-Oncological) Australian Medicines Handbook. Norethisterone. In: Australian References Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2017 [cited 2017 Apr 12]. -
Nur-Isterate Injection
SELECT THE REQUIRED INFORMATION PROFESSIONAL INFORMATION PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: NUR-ISTERATE Oily solution for intramuscular injection COMPOSITION: 1 ml contains norethisterone enantate (17-ethinyl-17-heptanoyloxy-4-estrene-3-one) 200 mg. Other ingredients are: benzyl benzoate, castor oil for injection. PHARMACOLOGICAL CLASSIFICATION: A. 21.8.2 Progesterones without estrogens. PHARMACOLOGICAL ACTION: Pharmacodynamic properties: Protection against conception is based primarily upon an alteration of the cervical mucous. This alteration is present for the whole of the duration of action and prevents the ascent of the sperm into the uterine cavity. Radioimmunological studies have shown that, during the first 5 to 7 weeks after injection, ovulation is suppressed as a result of the high plasma level of norethisterone. In addition, NUR- ISTERATE causes morphological changes in the endometrium which have the effect of rendering nidation of a fertilised egg difficult. Pharmacokinetic properties: Norethisterone enantate was completely absorbed after intramuscular injection. The ester was eventually completely hydrolysed to its pharmacologically active compound norethisterone once it was released from the depot. Maximum levels of norethisterone were measured at about 3 to 10 days after IM administration. They amounted on average to 13.4 5.4 ng/ml and 12.2 2.7 ng/ml about 7 days (median) after IM administration of 200 mg norethisterone enantate in 2 ml and 1 ml oily solution, respectively. Plasma levels of norethisterone declined in two disposition phases with half-lives of 4 to 5 days and 15 to 20 days, respectively, which were due to a biphasic release of norethisterone enantate from the depot. -
A Rare Case of Cerebral Venous Sinus Thrombosis (CVST) Induced by Norethisterone Enanthate: Report from a Medical University Hospital in Bangladesh
Case Report Annals of Clinical Case Reports Published: 25 Jan, 2019 A Rare Case of Cerebral Venous Sinus Thrombosis (CVST) Induced by Norethisterone Enanthate: Report from a Medical University Hospital in Bangladesh Raknuzzaman1, Anis Ahmed1*, Masud Rana1, Kazi Jannat Ara1 and Dewan Md Emdadul Hoque1 1Department of Neurology, Bangabandhu Sheikh Mujib Medical University, Bangladesh 2Department of Epidemiology and Preventive Medicine, International Centre for Diarrhoeal Disease Research, Bangladesh Abstract Cerebral Venous Sinus Thrombosis (CVST) is a rare condition and the association between norethisterone enanthate and CVST in the literature has very seldom been reported. In this case report, a 22-year-old unmarried woman of Bangladesh presented with acute onset of headache and vomiting with history of oral intake of 5 mg norethisterone thrice daily during past 2 years for menstrual disorder. She had no history of seizure, visual disturbances, and neck stiffness, imbalance of gait and weakness of any limbs, any sensory complaints or any episode of unconsciousness during the course of illness. Bilateral papilloedema was present with more marked on left eye and serum homocysteine level was high. A brain CT scan, MRI and Magnetic Resonance Venogram (MRV) revealed thrombosed anterosuperior segment of superior sagittal sinus. She was diagnosed to have CVST due to norethisterone and was treated with low molecular weight heparin, followed by Rivaroxaban, Vitamin B12, Vitamin B6 and Folic acid. She made a complete recovery after one month of intake of rivaroxaban and withdrawn of norethisterone. Keywords: Cerebral venous sinus thrombosis; Norethisterone enanthate; Hyperhomocysteinemia; OPEN ACCESS Rivaroxaban *Correspondence: Introduction Anis Ahmed, Department of Neurology, Cerebral Venous Sinuses Thrombosis (CVST) is rare type of stroke with the annual incidence Bangabandhu Sheikh Mujib Medical ranging from 0.22 to 1.57 per 100,000 populations, affecting young individuals and mostly women University, Bangladesh, Tel: [1-3]. -
Combined Estrogen–Progestogen Menopausal Therapy
PHARMACEUTICALS volume 100 A A review of humAn cArcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 14-21 October 2008 LYON, FRANCE - 2012 iArc monogrAphs on the evAluAtion of cArcinogenic risks to humAns COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). -
Pharmaceutical Appendix to the Tariff Schedule 2
Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9 -
Polycystic Ovarian Syndrome
Polycystic Ovarian Syndrome What we understand and how we can help October 2017 Presentation Title | 27 January 2014 History Stein and Leventhal 1935 Stein IF, Leventhal ML. Amenorrhoea associated with bilateral polycystic ovaries. Am J Obstet Gynaecol 1935; 29:181-191 Presentation Title | 7 January, 2019 Presentation Title | 7 January, 2019 Diagnosis Rotterdam criteria – Two of the three criteria 1. PCOS on USS 2. Oligo or anovulation (less than 6 periods each year) 3. Hyperandrogenism Presentation Title | 7 January, 2019 Presentation Title | 7 January, 2019 Diagnosis – ovarian morphology PCO ultrasound appearance in 22% of normal population PCOS is present in • 7% of women • 32% of women with amenorrhoea • 87% of women with hirsuitism/ acne • 73% of women with anovulatory infertility Presentation Title | 7 January, 2019 Diagnostic tests The biochemical tests are to identify hyperandrogenism… Testosterone Can be measured at any time during the cycle. Consider testosterone secreting tumour if rapid virilisation. Consider High total testosterone or normal total testosterone with low SHBG and high bio-testosterone (measure the free androgen index) GTT All PCOS women who are obese and all women PCOS women over the age of 40. LH and FSH AMH Ovarian reserve and number of antral follicles. – may be raised in PCOS, however not currently used in diagnsois. Presentation Title | 7 January, 2019 Presentation Title | 7 January, 2019 Managing Symptoms Presentation Title | 7 January, 2019 Obesity Supportive strategies for weight loss and diet. Consider Metformin Bariatric surgery Presentation Title | 7 January, 2019 Hirsuitism and Acne Weight loss Cosmetic methods Oral contraceptive pill consider Yasmin as it has an antiandrogenic action. -
TGA Review of Hgps
A REVIEW TO UPDATE AUSTRALIA’S POSITION ON THE HUMAN SAFETY OF RESIDUES OF HORMONE GROWTH PROMOTANTS (HGPs) USED IN CATTLE Prepared by Chemical Review and International Harmonisation Section Office of Chemical Safety Therapeutic Goods Administration of the Department of Health and Ageing Canberra July 2003 A draft of this report was tabled at the 25th Meeting of the Advisory Committee on Pesticides and Health (ACPH), held in Canberra on the 1st May 2003. The report was subsequently endorsed out-of-session by the ACPH. Hormone Growth Promotants TABLE OF CONTENTS ABBREVIATIONS ................................................................................................................................................................4 EXECUTIVE SUMMARY ..................................................................................................................................................7 INTRODUCTION..................................................................................................................................................................9 HEALTH CONCERNS ASSOCIATED WITH HGP S................................................................................................................9 DIFFICULTIES ASSOCIAT ED WITH ASSESSING THE SAFETY OF HGPS.........................................................................10 RISK ASSESSMENTS OF HGP S .........................................................................................................................................10 PURPOSE OF THE CURRENT